JAJintanat Ananworanich

Jintanat Ananworanich

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jintanat Ananworanich has a total of 62 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 15 August 2005
      • Vol. 39  (5) , 523-9

    Highly active antiretroviral therapy (HAART) retreatment in patients on CD4-guided therapy achieved similar virologic suppression compared with patients on continuous HAART: the HIV Netherlands Australia Thailand Research Collaboration 001.4 study.

    by Jintanat Ananworanich, Umaporn Siangphoe, Andrew Hill, Peter Cardiello, Wichitra Apateerapong, Bernard Hirschel, Apicha Mahanontharit, Sasiwimol Ubolyam, David Cooper, Praphan Phanuphak, et al.

    To assess the safety of 2 intermittent treatment strategies compared with continuous therapy for patients with virologic suppression on highly active antiretroviral therapy (HAART) at baseline. Seventy-four nucleoside reverse transcriptase inhibitor (NRTI) and protease inhibitor (PI) pretreated patients with an HIV RNA level 350 cells/microL and HIV RNA level <400 copies/mL at week 108. Patients were followed up every 12 weeks for CD4 count, HIV RNA level, and clinical and laboratory toxicities. In the CD4-guided arm, treatment was stopped and restarted using a CD4 count threshold (above or below 350 cells/microL or reduction of 30%). Seventy-four patients were enrolled with a median CD4 count of 644 cells/microL before the structured treatment interruption (STI). The week-on-week-off arm (n=26) was discontinued at week 72 because of high rates (46%) of HIV RNA rebound above 50 copies/mL. In the continuous arm, 25 (100%) of 25 patients and 24 (96%) of 25 patients had an HIV RNA level <400 copies/mL and <50 copies/mL, respectively, at week 108, and 96% had a CD4 count above 350 cells/microL, with a median CD4 count of 661 cells/microL. Patients in the CD4-guided arm had a significantly lower median CD4 count (489 cells/microL) than the patients in the continuous arm (P=0.03), but all had a CD4 count above 350 cells/microL and 1 had a new HIV-related illness. At week 108, 21 (91%) of 23 patients and 13 (57%) of 23 patients had an HIV RNA level <400 copies/mL and <50 copies/mL, respectively. Those who did not achieve an HIV RNA level <50 copies/mL had a higher HIV RNA load before retreatment, and 4 of 5 patients subsequently achieved viral suppression after an additional 12 weeks of HAART (week 120). Therefore, 17 (94%) of 18 evaluable CD4-guided arm patients achieved viral suppression after retreatment. Antiretroviral (ARV) side effects were similar in all arms. CD4-guided treatment had a 54% ARV cost savings. This pilot study suggests that CD4-guided HAART is a well-tolerated and cost-saving treatment strategy for patients with high pre-ARV and pre-STI CD4 counts. Week-on-week-off treatment had a high virologic failure rate and was discontinued. The HIV RNA suppression rate was similar in patients treated with continuous HAART and in those retreated with 12 to 24 weeks of HAART after CD4-guided therapy.


  • A Prospective Study of Efficacy and Safety of Once-Daily Saquinavir/Ritonavir plus Two Nucleoside Reverse Transcriptase Inhibitors in Treatment-Naive Thai Patients

    by Praphan Phanuphak, Sasiwimol Ubolyam, Jongkol Sankote, Patcharee Pongprayoon, Sukontha Saenawat, Saijai Wicharuk, Siriporn Nonenoy, Natnipa Wannachai, Sineenart Chautrakarn, Theshinee Chuenyam, et al.

    Objective: To assess the efficacy and safety of first-line treatment with once-daily saquinavir/ritonavir with two nucleoside reverse transcriptase inhibitors (NRTIs), as induction therapy before enrollment in a randomized trial of structured treatment interruption strategies. Design: Two-hundred antiretroviral-naive patients with CD4 + cell counts between 200–350 at screening were enrolled in this open-label 24week study. Methods: Patients were followed up every 8 weeks for CD4 + cells, HIV RNA, and clinical and laboratory toxicities. Results: Two-hundred patients were enrolled with median baseline CD4 + cell count of 267 cells/μl and HIV RNA 50 118 (4.7 log 10 ) copies/ml. After 24 weeks of treatment, 191 of 200 (96%) patients had below 400 copies/ml HIV RNA, with 177/200 (89%) below 50 copies/ml (intent to treat, missing equals failure method), with a median rise in CD4 + cell count of 122 cells/μl. There was no significant correlation between the minimum concentration of saquinavir and HIV RNA reductions at week 8 ( P=0.957) or absolute HIV RNA at week 24 ( P=0.77). Conclusion: First-line highly active antiretroviral therapy (HAART) with once-daily saquinavir/ritonavir plus two NRTIs showed strong antiviral efficacy over 24 weeks, and should be evaluated in larger prospective randomized clinical trials.


    • 1 March 2005
      • Vol. 23  (1) , 23-8

    No effect of interleukin-2 on IgE levels given in addition to antiretroviral therapy in HIV-infected adults with CD4 >300 cells/mm3.

    by Jintanat Ananworanich, Hiroshi Chantaphakul, Somsong Teeratakulpisarn, Umaporn Siangphoe, Sasiwimol Ubolyam, Theshinee Chuenyam, Chaiwat Ungsedhaphan, Joep Lange, David Cooper, Praphan Phanuphak, et al.

    HIV-infected patients may have frequent atopy caused by an imbalance of Th1 and Th2 cytokines. The objective of the present study was to investigate whether IL-2 given in addition to antiretrovirals (ARV) would result in lower IgE levels and less allergic symptoms. Patients naive to IL-2 (n=28) began IL-2 plus ARV and were followed for 12 months. IgE, eosinophil and CD4 counts, HIV RNA, symptom scoring, PFT and skin prick test (SPT) were performed. It was found that the baseline median CD4 and IgE were 386.5 cells/mm3 and 63.5 IU/ml, respectively. Four patients had allergic rhinitis (AR) and 61% had a positive SPT to at least 1 antigen. At month 12, patients had higher CD4 counts (p < 0.001) compared to the baseline; however, there were no differences in IgE levels, allergic symptom scores or HIV RNA. The eosinophil count was higher after IL-2 administration. It was concluded that IL-2 plus ARV resulted in higher CD4 counts but had no effect on atopy.

  • Open Access

    Development of HIV with Drug Resistance after CD4 Cell Count--Guided Structured Treatment Interruptions in Patients Treated with Highly Active Antiretroviral Therapy after Dual--Nucleoside Analogue Treatment

    by Reto Nuesch, Jintanat Ananworanich, Sunee Sirivichayakul, Sasiwimol Ubolyam, Umaporn Siangphoe, Andrew Hill, David Cooper, Joep Lange, Praphan Phanuphak, Kiat Ruxrungtham

    Background. For patients with human immunodeficiency virus (HIV) infection, structured treatment interruption (STI) is an attractive alternative strategy to continuous treatment, particularly in resource-restrained settings, because it reduces both side effects and costs. One major concern, however, is the development of resistance to antiretroviral drugs that can occur during multiple cycles of starting and stopping therapy. Methods. HIV genotypic drug resistance was investigated in 20 HIV-infected Thai patients treated with highly active antiretroviral therapy (HAART) and CD4 cell count—guided STI after dual nucleoside reverse-transcriptase inhibitor (NRTI) treatment. Resistance was tested at the time of the switch from dual-NRTI treatment to HAART and when HAART was stopped during the last interruption. Results. After STI, one major drug-resistance mutation occurred (T215Y), and, in the 4 samples with preexisting major mutations (D67N [n = 2], K70R [n = 2], T215Y [n = 2], and T215I [n = 1]), the mutations disappeared. All mutations in the HIV protease gene were minor mutations already present, in most cases, before STI was started, and their frequency was not increased through STI, whereas the frequency of reverse-transcriptase gene mutations significantly decreased after the interruptions. After the 48-week study period, no patients had virological failure. Long-term follow-up (108 weeks) showed 1 case of virological failure in the STI arm and 1 in the continuous arm. No virological failure was seen in patients with major mutations. Conclusions. Major HIV drug-resistance mutations were not induced through CD4 cell count—guided treatment interruptions in HIV-infected patients successfully treated with HAART after dual-NRTI therapy.


  • Open Access

    Resistance to Dual Nucleoside Reverse-Transcriptase Inhibitors in Children Infected with HIV Clade A/E

    by Rangsima Lolekha, Sunee Sirivichayakul, Umaporn Siangphoe, Chitsanu Pancharoen, Suchada Kaewchana, Wichitra Apateerapong, Apicha Mahanontharit, Tawee Chotpitayasunondh, Kiat Ruxrungtham, Praphan Phanuphak, et al.

    The prevalence of nucleoside reverse-transcriptase inhibitor (NRTI) mutations was determined among 95 human immunodeficiency virus—infected Thai children who were treated with dual nucleoside reverse-transcriptase inhibitors. Almost all children had resistance to at least 1 NRTI, and approximately half of the children had resistance to multiple NRTIs. Cross-resistance to stavudine and azidothymidine was universal.


  • Interrupting highly active antiretroviral therapy in patients with HIV

    by Jintanat Ananworanich, Bernard Hirschel

    Scheduled treatment interruptions are preplanned interruptions of antiretroviral treatment, which may be directed by time (e.g., cycles of 8 weeks on treatment and 8 weeks off treatment); the concentration of CD4+ lymphocytes (the CD4 count); HIV-1 RNA concentration (viral load); or other factors. This review covers the rationale of scheduled treatment interruptions and the different strategies that have been explored. It examines the issue of autovaccination, resistance and other risks and benefits. Scheduled-treatment-interruption studies in three populations are discussed: patients who initiated highly active antiretroviral therapy during acute HIV infection; patients with successfully treated chronic HIV infection; and patients with highly active antiretroviral therapy failure.


  • Incidence and risk factors for rash in Thai patients randomized to regimens with nevirapine, efavirenz or both drugs

    by Jintanat Ananworanich, Zewlan Moor, Umaporn Siangphoe, Jason Chan, Peter Cardiello, Chris Duncombe, Praphan Phanuphak, Kiat Ruxrungtham, Joep Lange, David A Cooper

    Objective: To determine the incidence and risk factors for rash in Thai patients taking four different non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens. Methods: HIV-positive, antiretroviral-naive patients enrolled in the 2NN study in Thailand and followed for at least 1 week were included. Patients were randomized to efavirenz (EFV) 600 mg once daily (OD) versus nevirapine (NVP) 200 mg twice daily (BD) versus NVP 400 mg OD versus NVP 400 mg OD + EFV 800 mg OD with stavudine/lamivudine. Results: Of 202 patients, 95 (47%) and 69 (34.2%) developed a rash from all reasons and from NNRTI, respectively. For NNRTI-related rash the incidences were EFV (20%), NVP BD (21%), NVP OD (38%) and NVP + EFV (67%). The proportions of patients with grade I, II and III within the four treatment arms are as follows: EFV, 4.3, 13 and 2.9%; NVP BD, 2.3, 15.9 and 2.3%; NVP OD, 12.8, 19.1 and 6.4%; and NVP + EFV, 11.9, 47.6 and 7.1%. Multivariate analyses showed females with CD4 cell count ≥250 × 106 cells/l, high body mass index (>21.3 kg/m2), and a rise in CD4 (≥53 × 106 cells/l) and alanine aminotransferase (ALT) (≥34 U/l) at week 4 to be risk factors for rash. Conclusions: Thai patients had a high incidence of NNRTI-related rash when treated with NVP + EFV or NVP OD. NVP if used BD had the same rash incidence as EFV for rash of all grades. Females, and persons with earlier HIV disease or with a large rise in CD4+ cell count after starting therapy are at greater risk for NNRTI-related rash


  • Creation of a drug fund for post-clinical trial access to antiretrovirals

    by Jintanat Ananworanich, Theshinee Cheunyam, Somsong Teeratakulpisarn, Mark A Boyd, Kiat Ruxrungtham, Joep Lange, David Cooper, Praphan Phanuphak


  • Open Access

    Recurring Thrombocytopenia Associated with Structured Treatment Interruption in Patients with Human Immunodeficiency Virus Infection

    by Jintanat Ananworanich, Nittaya Phanuphak, Reto Nuesch, Wichitra Apateerapong, Ponlapat Rojnuckarin, Sasiwimol Ubolyam, Praphan Phanuphak, Kiat Ruxrungtham

    In a structured treatment interruption (STI) trial, 3 of 23 patients in a CD4 cell count-guided treatment arm developed recurring thrombocytopenia ass